Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria

NCT04827589 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Development program terminated

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: Tirabrutinib
DRUG: Placebo

Sponsor

Gilead Sciences